Clinical Outcomes Among Patients with Tuberculous Meningitis Receiving Intensified Treatment Regimens

Overview

Journal Int J Tuberc Lung Dis

Specialty Pulmonary Medicine

Date 2021 Jul 31

PMID 34330348

Citations 6

Authors

A G C Smith

M Gujabidze

T Avaliani

H M Blumberg

J M Collins

S Sabanadze

T Bakuradze

Z Avaliani

R R Kempker

M Kipiani

Affiliations

Soon will be listed here.

Abstract

National Center for Tuberculosis and Lung Diseases (NCTLD), Tbilisi, Georgia. To determine clinical outcomes of patients with tuberculous meningitis (TBM) treated with an intensified regimen including a fluoroquinolone (FQ) and an injectable agent. Prospective cohort of patients aged ≥16 years initiating treatment for TBM at the NCTLD from January 2018 to December 2019. Treatment outcomes and neurologic disability at 1, 6 and 12 months after treatment initiation were assessed. Among 77 patients with median follow-up time of 363 days (IQR 269-374), 97% received a FQ, 62% an injectable agent, 44% linezolid and 39% a carbapenem. Fifty-seven patients (74%) successfully completed treatment, 2 (2.6%) had treatment failure, 6 (7.8%) died, and the remainder (12%) were lost to follow up. Among 11 patients treated for multidrug-resistant TBM, the median follow-up time was 467 days and one patient (8%) died. Regarding neurologic outcomes, 14/76 (18%) patients had Modified Rankin Scores of 0 at baseline, improving to 85% (56/66) and 94% (47/50) at 6 and 12 months, respectively. Intensified multidrug treatment regimens including a FQ and an injectable agent in all patients and newly implemented drugs in patients with multidrug-resistant TBM resulted in low mortality and favorable neurologic outcomes.

Citing Articles

Pharmacometabolomics in TB meningitis-Understanding the pharmacokinetic, metabolic, and immune factors associated with anti-TB drug concentrations in cerebrospinal fluid.

Collins J, Kipiani M, Jin Y, Sharma A, Tomalka J, Avaliani T PLoS One. 2025; 20(3):e0315999.

PMID: 40029856 PMC: 11875335. DOI: 10.1371/journal.pone.0315999.

Challenges of Multidrug-Resistant Tuberculosis Meningitis: Current Treatments and the Role of Glutathione as an Adjunct Therapy.

Nasiri M, Lutfy K, Venketaraman V Vaccines (Basel). 2025; 12(12.

PMID: 39772057 PMC: 11728556. DOI: 10.3390/vaccines12121397.

Extracorporeal membrane oxygenation in acute respiratory distress syndrome caused by elderly tuberculous meningitis: a case report and review of the literature.

Shi Z, Zhu X, Gao W, Yu S, Zhan L Front Med (Lausanne). 2024; 11:1457413.

PMID: 39359923 PMC: 11445011. DOI: 10.3389/fmed.2024.1457413.

Comprehensive Therapeutic Approaches to Tuberculous Meningitis: Pharmacokinetics, Combined Dosing, and Advanced Intrathecal Therapies.

Madadi A, Sohn M Pharmaceutics. 2024; 16(4).

PMID: 38675201 PMC: 11054600. DOI: 10.3390/pharmaceutics16040540.

Predictions of Bedaquiline Central Nervous System Exposure in Patients with Tuberculosis Meningitis Using Physiologically based Pharmacokinetic Modeling.

Mehta K, Balazki P, van der Graaf P, Guo T, van Hasselt J Clin Pharmacokinet. 2024; 63(5):657-668.

PMID: 38530588 PMC: 11106169. DOI: 10.1007/s40262-024-01363-6.

References

Mikiashvili L, Kipiani M, Schechter M, Avaliani Z, Kiria N, Kempker R . Linezolid use for drug-resistant tuberculosis in Georgia: a retrospective cohort study. Int J Tuberc Lung Dis. 2020; 24(4):436-443. PMC: 7385591. DOI: 10.5588/ijtld.19.0444. View

Thwaites G, Lan N, Dung N, Quy H, Oanh D, Thoa N . Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J Infect Dis. 2005; 192(1):79-88. DOI: 10.1086/430616. View

Gascua Adu-Gyamfi C, Savulescu D, George J, Suchard M . Indoleamine 2, 3-Dioxygenase-Mediated Tryptophan Catabolism: A Leading Star or Supporting Act in the Tuberculosis and HIV Pas-de-Deux?. Front Cell Infect Microbiol. 2019; 9:372. PMC: 6828849. DOI: 10.3389/fcimb.2019.00372. View

Baijnath S, Naiker S, Shobo A, Moodley C, Adamson J, Ngcobo B . Evidence for the presence of clofazimine and its distribution in the healthy mouse brain. J Mol Histol. 2015; 46(4-5):439-42. DOI: 10.1007/s10735-015-9634-3. View

Wen L, Li M, Xu T, Yu X, Wang L, Li K . Clinical features, outcomes and prognostic factors of tuberculous meningitis in adults worldwide: systematic review and meta-analysis. J Neurol. 2019; 266(12):3009-3021. DOI: 10.1007/s00415-019-09523-6. View

Wilson J, Pettigrew L, Teasdale G . Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. J Neurotrauma. 1998; 15(8):573-85. DOI: 10.1089/neu.1998.15.573. View

Zenner D, Kruijshaar M, Andrews N, Abubakar I . Risk of tuberculosis in pregnancy: a national, primary care-based cohort and self-controlled case series study. Am J Respir Crit Care Med. 2011; 185(7):779-84. DOI: 10.1164/rccm.201106-1083OC. View

Luque S, Grau S, Alvarez-Lerma F, Ferrandez O, Campillo N, Horcajada J . Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections. Int J Antimicrob Agents. 2014; 44(5):409-15. DOI: 10.1016/j.ijantimicag.2014.07.001. View

Munn D, Zhou M, Attwood J, Bondarev I, Conway S, Marshall B . Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998; 281(5380):1191-3. DOI: 10.1126/science.281.5380.1191. View

10.

Blassmann U, Roehr A, Frey O, Vetter-Kerkhoff C, Thon N, Hope W . Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study. Crit Care. 2016; 20(1):343. PMC: 5078935. DOI: 10.1186/s13054-016-1523-y. View

11.

Tsona A, Metallidis S, Foroglou N, Selviaridis P, Chrysanthidis T, Lazaraki G . Linezolid penetration into cerebrospinal fluid and brain tissue. J Chemother. 2010; 22(1):17-9. DOI: 10.1179/joc.2010.22.1.17. View

12.

Rock R, Olin M, Baker C, Molitor T, Peterson P . Central nervous system tuberculosis: pathogenesis and clinical aspects. Clin Microbiol Rev. 2008; 21(2):243-61, table of contents. PMC: 2292571. DOI: 10.1128/CMR.00042-07. View

13.

Banks J, Marotta C . Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke. 2007; 38(3):1091-6. DOI: 10.1161/01.STR.0000258355.23810.c6. View

14.

Mitnick C, Franke M, Rich M, Alcantara Viru F, Appleton S, Atwood S . Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. PLoS One. 2013; 8(3):e58664. PMC: 3596279. DOI: 10.1371/journal.pone.0058664. View

15.

Wang M, Luo L, Zhang Y, Liu X, Liu L, He J . Treatment outcomes of tuberculous meningitis in adults: a systematic review and meta-analysis. BMC Pulm Med. 2019; 19(1):200. PMC: 6833188. DOI: 10.1186/s12890-019-0966-8. View

16.

Mathad J, Gupta A . Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. Clin Infect Dis. 2012; 55(11):1532-49. PMC: 3491857. DOI: 10.1093/cid/cis732. View

17.

Cresswell F, Te Brake L, Atherton R, Ruslami R, Dooley K, Aarnoutse R . Intensified antibiotic treatment of tuberculosis meningitis. Expert Rev Clin Pharmacol. 2018; 12(3):267-288. DOI: 10.1080/17512433.2019.1552831. View

18.

Akkerman O, Odish O, Bolhuis M, de Lange W, Kremer H, Luijckx G . Pharmacokinetics of Bedaquiline in Cerebrospinal Fluid and Serum in Multidrug-Resistant Tuberculous Meningitis. Clin Infect Dis. 2015; 62(4):523-4. DOI: 10.1093/cid/civ921. View

19.

Vinnard C, King L, Munsiff S, Crossa A, Iwata K, Pasipanodya J . Long-term Mortality of Patients With Tuberculous Meningitis in New York City: A Cohort Study. Clin Infect Dis. 2016; 64(4):401-407. PMC: 5850536. DOI: 10.1093/cid/ciw763. View

20.

Wilkinson R, Rohlwink U, Misra U, van Crevel R, Mai N, Dooley K . Tuberculous meningitis. Nat Rev Neurol. 2017; 13(10):581-598. DOI: 10.1038/nrneurol.2017.120. View